Is Devonian Health Group Inc. (DVHGF) a Buy, Sell, or Hold?
OTC : DVHGF
Devonian Health Group Inc.
$7 USD
$0 (0.0%)
- Volume
- 100
- Average Volume
- 61
- Market Capitalization
- $19.47M
- P/E Ratio
- -4.46
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $10.80
- Year Low
- $4.27
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.91
Company Overview
OTC
Andre Boulet
Biotechnology
Healthcare
DVHGF
8
CA
USD
Liquidity Metrics
0.02
0.91
0.91
0.45
0.00
Sales & Valuation
$17.03M
10.27
3.87
-2.30
-4.26
Profitability
-$1.758
-$4.34M
-227.68%
-232.11%
-77.36%
-69.69%
P/E Metrics
-4.46
0.09
0.09
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-0.43
1/9
-$143.29K
$8.63M
$1.65M
-$11.13M
Key Metrics (TTM)
$26.54M
10.05
-2.43
0.91
-77.36%
-84.35%
-22.26%
-43.44%
-275 days
Company Executives
| Name | Title |
|---|---|
| Karine Blanchard Gagne | CEO of Executive Administrative Assistant |
| Andre Boulet | President, CEO, Chief Scientific Officer & Chair of the Board |
| Dennis Turpin | CFO & Director |
Poll Results
No votes yet today — be the first to share your view!
About Devonian Health Group Inc. (OTC:DVHGF) Stock
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was fo ... unded in 2015 and is based in Québec, Canada.
2026-07-27 21:00:00
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering PR Newswire
2026-07-27 20:00:00
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules.
2026-07-21 08:45:00
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability.
2026-06-29 21:00:00
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 PR Newswire
2026-06-29 20:00:00
(all amounts are in Canadian dollars) Quarter ended April 30, 2026, net loss of $1.9 million dollars, ($0.70) per share Nine months ended April 30, 2026, net loss of $5.7 million dollars, ($2.07) per share Cash as of April 30, 2026, $0.7 million Company remains debt-free QUÉBEC, June 29, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlighted its financial and operating results for the three and nine months ended April 30, 2026. ''We are pleased with the continued momentum to execute on our priorities and readiness to advance our pipeline'', said Dr. André P.
Frequently Asked Questions
-
What is the current Devonian Health Group Inc. (DVHGF) stock price?
-
Devonian Health Group Inc.(OTC:DVHGF) stock price is $7 in the last trading session. During the trading session, DVHGF stock reached the peak price of $10.8 while $4.266 was the lowest point it dropped to. The percentage change in DVHGF stock occurred in the recent session was 0.0% while the dollar amount for the price change in DVHGF stock was $0.
-
DVHGF's industry and sector of operation?
-
The OTC listed DVHGF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DVHGF?
-
Karine Blanchard Gagne | CEO of Executive Administrative Assistant
Andre Boulet | President, CEO, Chief Scientific Officer & Chair of the Board
Dennis Turpin | CFO & Director
|
| -
How many employees does DVHGF have?
-
Number of DVHGF employees currently stands at 8. DVHGF operates from 360, rue des Entrepreneurs, Québec, QC G5V 4T1, CA.
-
Link for DVHGF official website?
-
Official Website of DVHGF is: https://groupedevonian.com
-
How do I contact DVHGF?
-
DVHGF could be contacted at phone #+1 450 491 5555 and can also be accessed through its website. DVHGF operates from 360, rue des Entrepreneurs, Québec, QC G5V 4T1, CA.
-
How many shares of DVHGF are traded daily?
-
The average number of DVHGF shares traded daily for last 3 months was 61.
-
What is the market cap of DVHGF currently?
-
The market value of DVHGF currently stands at $19.47M with its latest stock price at $7